Clinical Characteristics of Colorectal Cancer Patients in terms of Selected Platelet Indices.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
01
2020
revised:
09
07
2020
accepted:
31
07
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
13
8
2021
Statut:
epublish
Résumé
Mounting evidence suggests that inflammation, immune response, and coagulation status determine many processes during the carcinogenesis pathway in colorectal cancer (CRC). Inflammation strongly promotes tumor formation, progression, and metastasis. The systemic inflammatory response (SIR) may be reflected by simple indicators evaluated on the basis of peripheral blood morphology parameters. The indices are easily obtained by the peripheral blood test and could be promising biomarkers for CRC. We present the results of the retrospective study evaluating the potential relation between the platelet indices (platelet count (PC), platelet-to-lymphocyte ratio (PLR), neutrophil platelet score (NPS), mean platelet volume (MPV), and MPV/PC ratio) and the clinicopathological features of CRC patients. The study included 247 patients (104 males and 143 females) aged 39-87 years with CRC stages II-IV. The complete blood counts with the automated differential counts were performed prior to the qualification to systemic treatment. High PC, high PLR, and NPS 0 were associated with older age and higher BMI of the patients. No link between the analyzed platelet indices and histological grade of the tumor, primary tumor location, and gender was noted. The patients aged ≥65 years were characterized by the higher MPV/PC ratio than the younger population. We observed a trend to the higher MPV/PC ratio among the patients with excessive body weight defined by BMI compared to BMI within normal limits. A higher frequency of PC > 400, NPS 1 and 2, and a trend to more frequent PLR ≥ 150 were observed in the subgroup with metastatic disease compared to individuals with CRC stages II and III. The presented results expand the knowledge on potential association between SIR parameters and other clinicopathological factors that should be considered during interpreting the prognostic and predictive value of the inflammation parameters.
Identifiants
pubmed: 33133303
doi: 10.1155/2020/6145604
pmc: PMC7568811
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6145604Informations de copyright
Copyright © 2020 Angelika Copija et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
J Clin Invest. 1988 Apr;81(4):1012-9
pubmed: 3280598
Oncotarget. 2017 May 9;8(19):32356-32369
pubmed: 28404961
BMC Cancer. 2019 Jan 7;19(1):15
pubmed: 30612568
Sci Rep. 2017 Dec 1;7(1):16717
pubmed: 29196718
Med Oncol. 2014 Oct;31(10):239
pubmed: 25218270
Oncotarget. 2017 Jun 19;8(40):68837-68846
pubmed: 28978160
Cancer Cell. 2013 Jul 8;24(1):130-7
pubmed: 23810565
BMC Cancer. 2019 Apr 4;19(1):314
pubmed: 30947696
Onco Targets Ther. 2017 Apr 18;10:2199-2208
pubmed: 28458563
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
Curr Med Res Opin. 2018 May;34(5):857-863
pubmed: 29161926
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2840-9
pubmed: 25249326
Medicine (Baltimore). 2019 Mar;98(9):e14740
pubmed: 30817629
World J Gastroenterol. 2014 Jul 14;20(26):8583-91
pubmed: 25024612
Dis Markers. 2019 Jan 17;2019:6036979
pubmed: 30800188
Dis Markers. 2017;2017:1053125
pubmed: 28539688
Nutr Res. 2011 Mar;31(3):197-204
pubmed: 21481713
Annu Rev Biomed Eng. 2009;11:177-202
pubmed: 19413512
PLoS One. 2018 Dec 4;13(12):e0208547
pubmed: 30513126
J Nutr Biochem. 2012 Oct;23(10):1207-13
pubmed: 22209007
Iran J Basic Med Sci. 2014 Aug;17(8):577-82
pubmed: 25422750
Expert Rev Anticancer Ther. 2008 Aug;8(8):1247-55
pubmed: 18699763
Cytokine Growth Factor Rev. 2011 Apr;22(2):83-9
pubmed: 21377916
Sci Rep. 2017 Nov 30;7(1):16609
pubmed: 29192175
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
Immunity. 2004 Aug;21(2):137-48
pubmed: 15308095
Int J Cancer. 1988 Oct 15;42(4):554-7
pubmed: 3170028
Med Oncol. 2013 Mar;30(1):439
pubmed: 23307251
Oncotarget. 2016 May 31;7(22):33210-9
pubmed: 27120807
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Obes Rev. 2009 Sep;10(5):554-63
pubmed: 19460118
Sci Rep. 2017 Aug 31;7(1):10261
pubmed: 28860547
PLoS One. 2015 Nov 06;10(11):e0142159
pubmed: 26544968
Dis Colon Rectum. 2019 Apr;62(4):498-508
pubmed: 30844974
Platelets. 2002 Aug-Sep;13(5-6):301-6
pubmed: 12189016
Cancer Res. 1999 Mar 15;59(6):1295-300
pubmed: 10096562
Oncotarget. 2016 Jan 5;7(1):1014-28
pubmed: 26510910
Surg Today. 2020 Mar;50(3):223-231
pubmed: 31485750
Med Oncol. 2015 May;32(5):144
pubmed: 25807934
Asian Pac J Cancer Prev. 2014;15(23):10501-4
pubmed: 25556499
Int J Surg. 2015 Jun;18:1-6
pubmed: 25843227